A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council.

Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi are not without risk, and their use is not appropriate for all patients with AD, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD.

Objectives: To provide a consensus expert opinion statement from the International Eczema Council (IEC) that provides a pragmatic approach to prescribing JAKi, including choosing appropriate patients and dosing, clinical and laboratory monitoring and advice about long-term use.

Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort.

Background: Upadacitinib was the first JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real-world data on the use of upadacitinib in patients that have been treated with other immunosuppressants and targeted therapies is limited.

Objectives: To provide real-world evidence on the use of upadacitinib treatment in moderate-to-severe atopic dermatitis.

Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis.

Background: Abrocitinib is a JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in phase 3 clinical trials, data on real-world patients with a treatment history of advanced systemics are scarce.

Objectives: The objective of the study was to evaluate the effectiveness and safety of abrocitinib treatment in patients with difficult-to-treat AD in daily practice.

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice.

Background: Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited.

Aim: To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD.

Methods: In this observational prospective study, patients with AD who received tralokinumab treatment in the context of routine care at the Erasmus Medical Centre were included between November 2021 and February 2022.

Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.

Background: Flushing and erythema are frequent skin symptoms in rosacea. Because their adequate treatment remains a clinical challenge, new treatment options are explored, such as oral β-blockers.

Objectives: To evaluate the efficacy of oral β-blockers for rosacea-associated facial flushing and erythema.

Anatomical site variation of water content in human skin measured by the Epsilon: A pilot study.

Background: This pilot study aimed to investigate the anatomical site variation of water content of the stratum corneum (SC) on the body by measuring skin capacitance with the Epsilon, a new generation corneometer with multiple sensors. Secondly, values of the Epsilon were compared to values measured by conventional single sensor corneometers.

Methods: The hydration status of SC was measured in 15 healthy Caucasian volunteers with the Epsilon at five body sites (cheek, lower forearm, mid-calf, lower back and abdomen).